Legend Biotech Corporation - American Depositary Shares (LEGN)
38.10
+0.88 (2.36%)
Legend Biotech Corp is a biotechnology company focused on the development and commercialization of innovative cell therapies for the treatment of cancer and other serious diseases
The company leverages its proprietary technologies to create advanced cellular therapies, particularly in the realm of engineered T cell therapy, aiming to harness the body's immune system to target and eliminate malignant cells. Through rigorous research and clinical trials, Legend Biotech is committed to addressing unmet medical needs and enhancing patient outcomes in the field of oncology.
SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQLEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday, January 14, 2025, at 3:45 p.m. PT.
SOMERSET, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQLEGN) (Legend Biotech), a global leader in cell therapy, announced today new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) provided significantly higher rates of minimal residual disease (MRD)-negativity in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD, compared to standard therapies of pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd).1 MRD negativity is a prognostic marker of prolonged survival outcomes for patients with multiple myeloma.1 These results reinforce the clinical value of CARVYKTI® as early as second line and support the recent achievement of overall survival (OS) benefit versus standard therapies1. The MRD negativity findings were featured as an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract #1032) in San Diego, California.1
SOMERSET, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQLEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, December 8, 2024, at 8:00 p.m. PT (11:00 p.m. ET) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA.
New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma
SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQLEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, November 12, 2024, to review third-quarter 2024 results.
New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell therapy leader
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by 45% compared to standard therapies.
SOMERSET, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQLEGN) (Legend Biotech), a global leader in cell therapy, today announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study that shows a single infusion of CARVYKTI® (ciltacabtagene autoleucel) significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), and an immunomodulatory agent (IMiD), reducing the risk of death by 45 percent versus standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).1 CARVYKTI® is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as second line.1 These results were presented as a late-breaking oral presentation at the 2024 International Myeloma Society (IMS) Annual Meeting (Abstract #OA-65) in Rio de Janeiro, Brazil.1
SOMERSET, N.J., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQLEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on Wednesday, September 4, 2024, at 2:35 p.m. ET.
SOMERSET, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQLEGN) (Legend Biotech), a global leader in cell therapy, today reported its second quarter 2024 unaudited financial results and key corporate highlights.
